268203-93-6
268203-93-6
Chemical Structure
Udenafil
Synonym(s): DA8159
- CAS No.: 268203-93-6
- Formula:C25H36N6O4S
- Molecular Weight:516.66
IUPAC Name: 3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-(2-(1-methylpyrrolidin-2-yl)ethyl)-4-propoxybenzenesulfonamide
InChIKey: IYFNEFQTYQPVOC-UHFFFAOYSA-N
SMILES: O=S(C1=CC=C(OCCC)C(C2=NC3=C(N(C)N=C3CCC)C(N2)=O)=C1)(NCCC4N(C)CCC4)=O
Biological Activity: Udenafil (DA8159) is a potent, selective and orally active phosphodiesterase type 5 (PDE5) inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Udenafil | 99.28% | Udenafil (DA8159) is a potent, selective and orally active phosphodiesterase type 5 (PDE5) inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Udenafil (Standard) | ≥98% | Udenafil (Standard) is the analytical standard of Udenafil. This product is intended for research and analytical applications. Udenafil (DA8159) is a potent, selective and orally active phosphodiesterase type 5 (PDE5) inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Udenafil-d7 | Udenafil-d7 is the deuterium labeled Udenafil. Udenafil (DA8159) is a potent, selective and orally active phosphodiesterase type 5 (PDE5) inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Paick, J.S., et al., The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med, 2008. 5(4): p. 946-53. [Content Brief]
- [2]. Zhao, C., et al., Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int, 2011. 107(12): p. 1943-7. [Content Brief]
